Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.
Daniel F Hanley, Richard E Thompson, Michael Rosenblum, Gayane Yenokyan, Karen Lane, Nichol McBee, Steven W Mayo, Amanda J Bistran-Hall, Dheeraj Gandhi, W Andrew Mould, Natalie Ullman, Hasan Ali, J Ricardo Carhuapoma, Carlos S Kase, Kennedy R Lees, Jesse Dawson, Alastair Wilson, Joshua F Betz, Elizabeth A Sugar, Yi Hao, Radhika Avadhani, Jean-Louis Caron, Mark R Harrigan, Andrew P Carlson, Diederik Bulters, David LeDoux, Judy Huang, Cully Cobb, Gaurav Gupta, Ryan Kitagawa, Michael R Chicoine, Hiren Patel, Robert Dodd, Paul J Camarata, Stacey Wolfe, Agnieszka Stadnik, P Lynn Money, Patrick Mitchell, Rosario Sarabia, Sagi Harnof, Pal Barzo, Andreas Unterberg, Jeanne S Teitelbaum, Weimin Wang, Craig S Anderson, A David Mendelow, Barbara Gregson, Scott Janis, Paul Vespa, Wendy Ziai, Mario Zuccarello, Issam A Awad, MISTIE III Investigators
Author Information
Daniel F Hanley: Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA. Electronic address: dhanley@jhmi.edu.
Richard E Thompson: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Michael Rosenblum: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Gayane Yenokyan: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Karen Lane: Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.
Nichol McBee: Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.
Steven W Mayo: Emissary International, Austin, TX, USA.
Amanda J Bistran-Hall: Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.
Dheeraj Gandhi: University of Maryland, Baltimore, MD, USA.
W Andrew Mould: Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.
Natalie Ullman: The Children's Hospital, Philadelphia, PA, USA.
Hasan Ali: Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.
J Ricardo Carhuapoma: School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Carlos S Kase: Emory University, Atlanta, GA, USA.
Kennedy R Lees: School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK.
Jesse Dawson: Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Alastair Wilson: School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK.
Joshua F Betz: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Elizabeth A Sugar: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Yi Hao: Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.
Radhika Avadhani: Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.
Jean-Louis Caron: University of Texas Health, San Antonio, TX, USA.
Mark R Harrigan: University of Alabama, Birmingham, AL, USA.
Andrew P Carlson: University of New Mexico, Albuquerque, NM, USA.
Diederik Bulters: University Hospital Southampton NHS Foundation Trust, Southampton, UK.
David LeDoux: Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA.
Judy Huang: School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Cully Cobb: Mercy Neurological Institute Stroke Center, Sacramento, California, USA.
Gaurav Gupta: Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Ryan Kitagawa: University of Texas, McGovern Medical Center, Houston, TX, USA.
Michael R Chicoine: Washington University School of Medicine, St Louis, MO, USA.
Hiren Patel: Salford Royal Hospital, Salford, UK.
Robert Dodd: Stanford University School of Medicine, Stanford, California, USA.
Paul J Camarata: University of Kansas, Kansas City, KS, USA.
Stacey Wolfe: Wake Forest School of Medicine, Winston-Salem, NC, USA.
Agnieszka Stadnik: University of Chicago, Chicago, IL, USA.
P Lynn Money: University of Chicago, Chicago, IL, USA.
Patrick Mitchell: Newcastle Royal Infirmary, Newcastle, UK.
Rosario Sarabia: Hospital Universitario Rio Hortega, Valladolid, Spain.
Sagi Harnof: Rabin Medical Center, Petah Tikva, Israel.
Pal Barzo: University of Szeged, Szeged, Hungary.
Andreas Unterberg: University of Heidelberg, Heidelberg, Germany.
Jeanne S Teitelbaum: Montreal Neurological Institute and Hospital at McGill University, Montreal, QC, Canada.
Craig S Anderson: The George Institute for Global Health China at Peking University Health Science Center, Beijing, China; The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
A David Mendelow: Newcastle University, Newcastle, UK.
Barbara Gregson: Newcastle University, Newcastle, UK.
Scott Janis: National Institutes of Health, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Paul Vespa: University of California, Los Angeles, CA, USA.
Wendy Ziai: Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.
Mario Zuccarello: University of Cincinnati, Cincinnati, OH, USA.
Issam A Awad: University of Chicago, Chicago, IL, USA.
BACKGROUND: Acute stroke due to supratentorial intracerebral haemorrhage is associated with high morbidity and mortality. Open craniotomy haematoma evacuation has not been found to have any benefit in large randomised trials. We assessed whether minimally invasive catheter evacuation followed by thrombolysis (MISTIE), with the aim of decreasing clot size to 15 mL or less, would improve functional outcome in patients with intracerebral haemorrhage. METHODS: MISTIE III was an open-label, blinded endpoint, phase 3 trial done at 78 hospitals in the USA, Canada, Europe, Australia, and Asia. We enrolled patients aged 18 years or older with spontaneous, non-traumatic, supratentorial intracerebral haemorrhage of 30 mL or more. We used a computer-generated number sequence with a block size of four or six to centrally randomise patients to image-guided MISTIE treatment (1·0 mg alteplase every 8 h for up to nine doses) or standard medical care. Primary outcome was good functional outcome, defined as the proportion of patients who achieved a modified Rankin Scale (mRS) score of 0-3 at 365 days, adjusted for group differences in prespecified baseline covariates (stability intracerebral haemorrhage size, age, Glasgow Coma Scale, stability intraventricular haemorrhage size, and clot location). Analysis of the primary efficacy outcome was done in the modified intention-to-treat (mITT) population, which included all eligible, randomly assigned patients who were exposed to treatment. All randomly assigned patients were included in the safety analysis. This study is registered with ClinicalTrials.gov, number NCT01827046. FINDINGS: Between Dec 30, 2013, and Aug 15, 2017, 506 patients were randomly allocated: 255 (50%) to the MISTIE group and 251 (50%) to standard medical care. 499 patients (n=250 in the MISTIE group; n=249 in the standard medical care group) received treatment and were included in the mITT analysis set. The mITT primary adjusted efficacy analysis estimated that 45% of patients in the MISTIE group and 41% patients in the standard medical care group had achieved an mRS score of 0-3 at 365 days (adjusted risk difference 4% [95% CI -4 to 12]; p=0·33). Sensitivity analyses of 365-day mRS using generalised ordered logistic regression models adjusted for baseline variables showed that the estimated odds ratios comparing MISTIE with standard medical care for mRS scores higher than 5 versus 5 or less, higher than 4 versus 4 or less, higher than 3 versus 3 or less, and higher than 2 versus 2 or less were 0·60 (p=0·03), 0·84 (p=0·42), 0·87 (p=0·49), and 0·82 (p=0·44), respectively. At 7 days, two (1%) of 255 patients in the MISTIE group and ten (4%) of 251 patients in the standard medical care group had died (p=0·02) and at 30 days, 24 (9%) patients in the MISTIE group and 37 (15%) patients in the standard medical care group had died (p=0·07). The number of patients with symptomatic bleeding and brain bacterial infections was similar between the MISTIE and standard medical care groups (six [2%] of 255 patients vs three [1%] of 251 patients; p=0·33 for symptomatic bleeding; two [1%] of 255 patients vs 0 [0%] of 251 patients; p=0·16 for brain bacterial infections). At 30 days, 76 (30%) of 255 patients in the MISTIE group and 84 (33%) of 251 patients in the standard medical care group had one or more serious adverse event, and the difference in number of serious adverse events between the groups was statistically significant (p=0·012). INTERPRETATION: For moderate to large intracerebral haemorrhage, MISTIE did not improve the proportion of patients who achieved a good response 365 days after intracerebral haemorrhage. The procedure was safely adopted by our sample of surgeons. FUNDING: National Institute of Neurological Disorders and Stroke and Genentech.
Associated Data
ClinicalTrials.gov | NCT01827046
References
Lancet. 2013 Aug 3;382(9890):397-408
[PMID: 23726393]
